HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


L’Oreal Optimistic About Post-Shutdown Growth, Notes Likely Thinning Of Beauty Field

Executive Summary

“It's unfortunate, but it's the Darwinian side of this industry,” L’Oreal CEO Jean-Paul Agon said on 16 April while discussing newer players’ prospects for survival through the COVID-19 crisis and L’Oreal’s own first-quarter results – down 4.8% like-for-like, but ahead of the market.

You may also be interested in...

L’Oreal To Fuel Continued Dermocosmetics Growth With Skinbetter Science Acquisition

Phoenix, AZ-based Skinbetter Science “has become one of the fastest growing medical-dispensed skincare brands in the United States,” recording nearly $95m in sales for the 12-month period ended 31 August 2022, and shows “great international potential,” according to L’Oreal leadership.

Dermocosmetics Opportunity Beckons: Top 20 Brands Account For Just 35% Of Global Market – IQVIA

The global dermocosmetics market is led by L’Oréal SA with 13.3% share across 20 countries evaluated, followed by Pierre Fabre Group with 7.4%. According to IQVIA Consumer Health, this points to a fragmented market with ample room for innovative, “nimble” brands to enter and nab share.

L’Oreal Powering Down Clarisonic After 16 Years Of Innovation, More Than 15 Million Devices Sold

The decision to close Clarisonic follows a 234m impairment charge recorded in 2016 and comes as L’Oreal faces tough strategic decisions in a global economy ravaged by the COVID-19 crisis.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts